Your browser doesn't support javascript.
Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis.
Shumilov, Evgenii; Aperdannier, Lena; Schmidt, Nicole; Szuszies, Christoph; Neesse, Albrecht; Hoffknecht, Petra; Khandanpour, Cyrus; Mikesch, Jan-Henrik; Stelljes, Matthias; Boeckel, Göran Ramin; Tepasse, Phil-Robin; Reitnauer, Lea; Koch, Raphael; Hasenkamp, Justin; Bacher, Ulrike; Scheithauer, Simone; Trümper, Lorenz; Schmitz, Norbert; Wulf, Gerald; Kerkhoff, Andrea; Lenz, Georg; Krekeler, Carolin; Bleckmann, Annalen.
  • Shumilov E; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
  • Aperdannier L; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Schmidt N; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Szuszies C; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Neesse A; Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Hoffknecht P; Department of Thorax Oncology, Franziskus-Hospital Harderberg, Niels-Stensen-Kliniken, 49124 Georgsmarienhütte, Germany.
  • Khandanpour C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
  • Mikesch JH; Department of Hematology and Medical Oncology, University of Lübeck and University of Schleswig-Holstein, 23564 Lübeck, Germany.
  • Stelljes M; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
  • Boeckel GR; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
  • Tepasse PR; Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany.
  • Reitnauer L; Department of Medicine D for Nephrology and Rheumatology, University Hospital Münster, 48149 Münster, Germany.
  • Koch R; Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany.
  • Hasenkamp J; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
  • Bacher U; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Scheithauer S; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Trümper L; Central Hematology Laboratory, Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Schmitz N; Department of Infection Control and Infectious Diseases, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Wulf G; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Kerkhoff A; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
  • Lenz G; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany.
  • Krekeler C; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
  • Bleckmann A; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany.
Cancers (Basel) ; 14(15)2022 Jul 31.
Article in English | MEDLINE | ID: covidwho-1969100
ABSTRACT
COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analyzed SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated and non-vaccinated patients from three German cancer centers. Overall, 133 patients with SARS-CoV-2 were enrolled in pre- and post-vaccine eras 84 non-vaccinated and 49 vaccinated, respectively. A mild course of COVID-19 was documented more frequently in vaccinated patients (49% vs. 29%), while the frequency of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%, p = 0.023). Particularly, patients with hematologic neoplasms benefited from vaccination in this context (p = 0.031). Admissions to intermediate- and intensive-care units and the necessity of non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients, respectively. The median length of admission was 11 days for non-vaccinated and 5 days for vaccinated patients (p = 0.002). COVID-19 mortality was reduced by 83% in vaccinated patients (p = 0.046). Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively (p = 0.002). Although this study does not have enough power to perform multivariate analyses to account for confounders, it provides data on COVID-19 in non-vaccinated and vaccinated cancer patients and illustrates the potential benefits of COVID-19 vaccines for these patients.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Cancers14153746

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Cancers14153746